5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes

Details for Australian Patent Application No. 2009228797 (hide)

Owner Novartis AG

Inventors Garcia-Echeverria, Carlos

Agent Davies Collison Cave

Pub. Number AU-B-2009228797

PCT Pub. Number WO2009/118324

Priority 08153311.9 26.03.08 EP

Filing date 24 March 2009

Wipo publication date 1 October 2009

Acceptance publication date 19 July 2012

International Classifications

A61K 31/4745

A61K 45/06 Medicinal preparations containing active ingredients not provided for in groups

A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

21 October 2010 PCT application entered the National Phase

  PCT publication WO2009/118324 Priority application(s): WO2009/118324

19 July 2012 Application Accepted

  Published as AU-B-2009228797

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009228804-Method of viral inactivation of biological fluids by solvent/detergent-treatment

2009228795-Process for preparing orally administered dabigatran formulations